Company news

AstraZeneca PLC news in 2019

AstraZeneca PLC's news releases, calls and decks from 2019, newest first.

View company

Imfinzi granted US Orphan Drug Designation for

July 12, 2019

Forxiga receives positive EU CHMP opinion for

July 1, 2019

Fasenra receives positive EU CHMP opinion for self

July 1, 2019

Imfinzi improves overall survival at interim

June 27, 2019

Lynparza approved in Japan for 1st-line

June 19, 2019

Breztri Aerosphere (PT010) approved in Japan for

June 19, 2019

Bevespi Aerosphere approved by the Japanese

June 19, 2019

Lynparza approved in the EU for 1st-line

June 18, 2019

Calquence significantly prolonged the time patient

June 17, 2019

Publication of a Prospectus

June 12, 2019

Calquence Phase III ELEVATE-TN trial met primary

June 6, 2019

AstraZeneca: Where has all the cash gone?

June 5, 2019

Lynparza nearly doubled time patients lived with

June 3, 2019

Pooled analyses of the roxadustat global Phase III

May 10, 2019

Trastuzumab deruxtecan demonstrated clinically

May 8, 2019

Calquence PhIII ASCEND trial met primary endpoint

May 7, 2019

Qternmet XR approved in the US for type-2 diabetes

May 3, 2019

Lynparza receives positive EU CHMP opinion for 1st

April 29, 2019

AZN: Q1 2019 Results

April 26, 2019

Lynparza approved in EU for the treatment of germl

April 10, 2019

Global Pharmaceuticals: 2018 industry sales

April 9, 2019

Selumetinib gets Breakthrough Therapy Designation

April 1, 2019

Results of Placing

March 29, 2019

Proposed placing of new ordinary shares

March 29, 2019

AZ and Daiichi Sankyo enter collaboration in novel

March 29, 2019

Forxiga approved in Japan for type-1 diabetes

March 27, 2019

Forxiga approved in Europe for type-1 diabetes

March 25, 2019

US FDA grants saracatinib ODD for IPF

March 18, 2019

Lynparza receives positive EU CHMP opinion

March 1, 2019

Lynparza significantly delayed disease progression

February 26, 2019

Brilinta's PhIII THEMIS trial met primary endpoint

February 25, 2019

AstraZeneca Full-Year and Q4 2018 Results

February 14, 2019

US FDA grants Fasenra Orphan Drug Designation

February 6, 2019

US FDA grants Breakthrough Therapy Designation

February 5, 2019

EMA grants PRIME eligibility for MEDI8897

February 5, 2019

Forxiga receives positive EU CHMP opinion

February 1, 2019

Completion of divestment of US Synagis rights

January 25, 2019

AstraZeneca announces organisational changes

January 7, 2019

← Newer news releases

Decks in 2019